Aslam Malik

Dr. Smithey is the President, CEO, and Co-founder of Serán BioScience with over 30 years of experience in pharmaceutical R&D. He led the development of several breakthrough therapies, including Tukysa® for metastatic breast cancer. A recognized innovator, he has founded multiple biotech ventures and holds over 50 patents.

Kevin is a chemical engineer with over 40 years at Pfizer, where he played key roles in both R&D and manufacturing. He contributed to the development and production of several major therapies and led global initiatives in tech transfer, scale-up, and new technology. A career highlight was his leadership in Pfizer’s COVID-19 vaccine manufacturing effort.

Mr. Cozean is a Managing Director at Bain Capital Life Sciences and serves on the board of Serán BioScience. He brings deep experience in healthcare investing, with prior roles at Bain Capital Private Equity and McKinsey & Co. He holds an MBA from Harvard Business School, where he was a Baker Scholar, and a BS in Commerce from the University of Virginia.

Dr. Aggarwal is a Managing Partner at Vivo Capital with over two decades of experience investing in the life sciences sector. He has held leadership roles across venture capital, public market investing, and biopharma operations, including as Chief Business Officer at Ocera Therapeutics. Dr. Aggarwal holds an M.D. from Columbia University and a B.S. from Cornell University.

Dr. Mike Preigh brings over 30 years of experience in pharmaceutical development and manufacturing. He most recently served as CTO at Day One Biopharmaceuticals, where he led the CMC efforts for the approval and launch of Ojemda (tovorafenib). His career includes leadership roles at Array BioPharma and Pfizer, with a track record of advancing numerous therapies from IND through commercialization.